Production (Stage)
E
Windtree Therapeutics, Inc. WINT
$0.779 $0.03094.13% NASDAQ
Recommendation
Prev Close
$0.779
Volume
67,046
Avg Vol (90D)
2,034,595
Market Cap
$2.77M
Dividend & Yield
--
52-Week Range
$0.733 - $737.44
P/E (TTM)
--
EPS (TTM)
-$1,256.56
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Windtree Therapeutics (WINT) Targets Key Study Analysis for July 2025 WINT Stock News
5/22/2025 - GuruFocus
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned ...
5/22/2025 - GuruFocus
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned ...
5/22/2025 - GuruFocus
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
5/22/2025 - Globe Newswire
Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart ...
5/19/2025 - GuruFocus
Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference
5/19/2025 - Globe Newswire
Windtree Therapeutics Inc. Reports Q1 2025 Financial Results
5/17/2025 - TipRanks Financial Blog
Windtree Therapeutics (WINT) Registers Up to 42.17M Shares for Resale
5/16/2025 - GuruFocus
Windtree Therapeutics (WINT) Plans to Sell Over 42 Million Shares WINT Stock News
5/16/2025 - GuruFocus
Windtree Therapeutics announces resale of 42.17M shares by selling stockholders
5/16/2025 - Seeking Alpha - Healthcare
Windtree Therapeutics files to sell 42.17M shares of common stock for holders
5/16/2025 - The Fly
Windtree Therapeutics reports Q1 EPS ($4.63)
5/16/2025 - The Fly
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
5/16/2025 - Globe Newswire
WINT: Windtree Therapeutics Reveals Promising Data on Istaroxime WINT Stock News
5/12/2025 - GuruFocus
Windtree Therapeutics announces presentation highlighting istaroxime
5/12/2025 - TipRanks Financial Blog
Windtree Therapeutics announces presentation highlighting istaroxime
5/12/2025 - The Fly
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective ...
5/12/2025 - GuruFocus
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
5/12/2025 - Globe Newswire
Windtree Therapeutics (WINT) Eyes U.S. Exclusivity for Istaroxime WINT Stock News
5/6/2025 - GuruFocus
Why biotech firm Windtree Therapeutics is buying a Houston apartment complex
5/6/2025 - BizJournals.com - Nat'l Business News
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
5/6/2025 - Globe Newswire
Why biotech firm Windtree Therapeutics is buying a 436-unit apartment complex
5/5/2025 - Bizjournals.com - Comm. Real Estate
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acquisition WINT Stock News
5/1/2025 - GuruFocus
Windtree Therapeutics enters Assignment, Conditional Assumption Agreement
5/1/2025 - TipRanks Financial Blog
Windtree Therapeutics enters Assignment, Conditional Assumption Agreement
5/1/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$24.35M
EBIT (TTM)
-$24.52M
Net Income (TTM)
-$1.79M
Balance Sheet
Total Assets (Q)
$27.88M
Total Debt (Q)
$1.49M
Total Liabilities (Q)
$17.88M
Book Value Per Share (Q)
$38.99
Cash Flow
Cash from Operations (TTM)
-$15.40M
Cash from Investing (TTM)
-$12.00K
Cash from Financing (TTM)
$12.73M
Net Change in Cash (TTM)
-$2.68M
Filings
Filing Date
Tuesday, April 15, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.68
7-Day Total Return
-6.14%
30-Day Total Return
-41.43%
60-Day Total Return
-75.50%
90-Day Total Return
-93.59%
Year to Date Total Return
-95.40%
1-Year Total Return
-99.60%
2-Year Total Return
-99.94%
3-Year Total Return
-100.00%
5-Year Total Return
-100.00%
52-week Low
May 22, 2025 - $0.733
52-week High
Aug 07, 2024 - $737.44
Valuation
Market Cap
$2.77M - Nano Cap
Enterprise Value
$3.18M
Price/Sales (TTM)
--
Price/Book (Q)
0.02
Dividends and Shares
Shares Outstanding
171.80K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
windtreetx.com
Phone Number
215 488 9300
Address
2600 Kelly Road
Warrington, PA 18976-3622
Country
United States
Year Founded
1992
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed